Categories
Health

Dr. Peter Hotez backs Fauci in his showdown with Sen. Paul over masks

Dr. Peter Hotez stands after a showdown between Republican Senator Rand Paul and Dr. Anthony Fauci on Capitol Hill for masks on the side of one of the best doctors in the country.

“Dr. Fauci is absolutely right, Senator Paul is absolutely wrong, and it has been for the past 14 months,” said Hotez.

Paul claimed that after their recovery or vaccination, people are not at risk for Covid and therefore do not need to wear masks. The Kentucky Senator also claimed that Fauci was just sporting two masks.

The White House chief medical officer strongly opposed Paul’s comments Thursday during a Senate hearing examining the country’s efforts to respond to the coronavirus.

“I can only say that masks are no theater,” said Fauci. “I totally disagree with you.”

In a Thursday night interview on The News with Shepard Smith, Hotez noted that “masks may need to be removed” but that it is too early and “we are still trying to understand the full performance characteristics of the vaccines”.

“We are only now getting a clue that it is interrupting the asymptomatic transmission,” said Hotez.

The masks debate comes from the fact that almost half of the country has seen an increase in Covid cases. 23 states reported an average of seven days increase in cases last week, according to Johns Hopkins. Half a dozen states are also seeing a higher trend in hospital stays, according to the Department of Health and Human Services.

Hotez, co-director of the Center for Vaccine Development at Texas Children’s Hospital, told host Shepard Smith that the spikes could be the result of highly transmissible new variants.

“The key now is to vaccinate before the variants as soon as possible,” said Hotez.

Categories
Entertainment

Peter G. Davis, Music Critic of Vast Data and Wit, Dies at 84

Peter G. Davis, who was considered one of the leading critics of American classical music for over 30 years with crisp, witty prose and an encyclopedic memory of countless performances and performers, died on February 13th. He was 84 years old.

His death was confirmed by his husband, Scott Parris.

First as a critic for the New York Times and later for New York Magazine, Mr. Davis wrote precise, astute reviews of all forms of classical music, though his great love was opera and the voice, a bond he developed in his early teenage years .

He presided over the field during New York’s blessing years of the 1960s and 1970s, when gigs were plentiful, tickets were relatively cheap, and when the ups and downs of a performer’s career were the fodder for cocktail parties and post-concert dinners to mention the notebooks of writers like Mr. Davis, which often got five or more reviews a week.

He wrote these reviews with a knowing, dead, sometimes world-weary tone. During a concert by Russian violinist Vladimir Spivakov in 1976, an activist protesting the treatment of Jews in the Soviet Union threw a paint bomb on the stage and splashed Mr. Spivakov and his companion. Mr Davis wrote, “Terrorists need to be extremely insensitive to music because throwing color to a violinist playing Bach’s ‘Chaconne’ is simply bad timing.”

He held onto the traditions of classical music not to keep the past alive but to keep its inner strength, and looked askance at those who tried to update it just to be trendy.

In a nineteenth-century review by French composer Daniel Francois Auber of the Bronx Opera’s 1977 production of Fra Diavolo, he condemned what he saw as “a refusal to believe in the piece by doing it treated as an embarrassment, a work that needs a maximum of directing gimmicks if the audience is to stay interested. “

He might equally disapprove of new music and composers whom he thought were overly hyped. Minimalist composers Philip Glass and Beverly Sills (early “a reliable, hardworking, but not particularly notable soprano” who only became a star after her talents peaked) were regular targets.

Looking back at a performance of Mr. Glass’s work at Carnegie Hall in 2002, he wrote, “It was pretty much the same as usual: the same silly syncopation and jigging ostinatas, the same crazy little tunes on their way to nowhere. the same awkward orchestral climaxes. “

That’s not to say that Mr. Davis was a reactionary – he advocated for young composers and emerging regional opera companies. His great strength as a critic was his pragmatism, his commitment to assessing the performance before him on his own terms and at the same time keeping a skeptical eye on gimmicks.

“He was a vocalist with unquestionable authority,” said Justin Davidson, a former Newsday classical music critic who now writes on classical music and architecture for New York magazine. “He felt that the things that were important to him were important, that they weren’t a niche, not just entertainment, but that they were at the heart of American culture.”

Peter Graffam Davis was born on May 3, 1936 in Concord, Massachusetts, outside of Boston, and grew up in nearby Lincoln. His father, E. Russell Davis, was a vice president at the Bank of Boston. His mother Susan (Graffam) Davis was a housewife.

Mr. Parris, whom he married in 2009, is his only immediate survivor.

Mr. Davis fell in love with the opera as a teenager, built a record collection at home, and attended performances in Boston. In the months leading up to his junior year at Harvard, he toured European summer music festivals – Strauss in Munich, Mozart in Salzburg, Wagner in Bayreuth.

He encountered European opera at a hinge point. It was still shaped by longstanding traditions and had yet to emerge fully from the destruction of World War II, but a new generation of performers emerged from the rubble: the French soprano Régine Crespin, the Austrian soprano Leonie Rysanek, the Italian tenor Franco Corelli and Giuseppe di Stefano. Mr. Davis needed to see her up close.

He graduated from Harvard in 1958 with a bachelor’s degree in music. After spending a year at a Stuttgart Conservatory, he moved to New York to do a Masters in Composition from Columbia University.

Mr. Davis wrote a number of his own musical works in the early 1960s, including the opera “Zoe” and two operettas in the style of Gilbert and Sullivan. But he decided that his future was not to write music, but to write about it. He has become a classical music editor for both High Fidelity and Musical America magazines and a New York music correspondent for The Times of London.

He began writing freelance articles for the New York Times in 1967 and was hired as Sunday’s music editor in 1974, a job that enabled him to add articles to his almost daily edition of reviews – whether it be recordings, concerts, or countless debut evenings which he commissioned from other authors. “He had a great memory,” said Alex Ross, the classical music critic for The New Yorker. “Everything you threw at him he could discuss precisely and intelligently.”

Mr. Davis moved to New York Magazine in 1981. There he could select his reviews and occasionally step back to survey the classical music landscape.

Increasingly, he didn’t like what he saw.

As early as 1980, Mr. Davis lamented the future of opera singing, blaming talent and hard work as well as a star system that pushed promising but immature singers to their physical limits for “good looks and easy adaptability.”

The diminished position of classical music in American culture he documented spared no critics, and in 2007 New York magazine let him go. He returned to freelance work for The Times, writing regularly for Opera News and Musical America.

Despite all of his thousands of reviews, Mr. Davis seemed most proud of his 1997 book, The American Opera Singer, an exhaustive, exciting, and often withered story in which he praised the versatility of contemporary American artists while recording many of them Task of being superficial workhorses.

“I can’t think of a music critic who cares more about the state of opera in America,” wrote critic Terry Teachout in his review of the book for The Times. “If you want to know what’s wrong with American singing, you’ll find the answers here.”

Categories
Entertainment

Who Performs Younger Peter and Lara Jean in To All of the Boys 3?

Long before Peter Kavinsky and Lara Jean Covey made college plans, they were kids who grew up together. We don’t get much glimpse into her pre-high school life in the Netflix movies, but in To all boys: always and forever Fans are blessed with a little look back at their middle school days. That sweet moment shows where the story of Peter and LJ began, but who actually played the younger versions of the characters we know and love? It turns out that both actors came from another popular Netflix project: The babysitting club.

Momona Tamada and Rian McCririck stepped in the shoes of Lara Jean and Peter for the final episode of To All the Boys, which premiered on February 12th. “So lucky I got a little role on this project and met the author of this incredible book, movie,” McCririck wrote on Instagram, along with a photo of him and Tamada with writer Jenny Han. When Tamada and McCririck aren’t playing young Covey and Kavinsky, they bring Claudia Kishi and Logan Bruno to life. There is something special about those onscreen projects that start out as books, don’t they? I can’t wait to see more of these two The babysitting clubSeason two is (hopefully) coming to Netflix soon.

Categories
World News

Trend Mogul Peter Nygard Denied Bail by Canadian Choose

Mr Nygard appeared in court via video link from prison and looked like the shell of the man who was once plastered on billboards in New York’s Times Square and Winnipeg Airport. His gray hair, usually covered in a lion’s mane, was tied in a messy bun. He was wearing a face mask and gray-blue shirt while in jail and stared straight ahead without reacting to the judge’s decision.

Updated

Apr. 5, 2021 at 4:14 pm ET

Denied bail is relatively rare in Canada, especially for those with no criminal record like Mr Nygard, said Seth Weinstein, a Toronto criminal defense attorney who co-authored a book on extradition cases.

Mr Prober said he would wait for more information on the charges from the US prosecutor’s office before deciding on his client’s next steps. It is very unlikely that a challenge from Mr Nygard to his extradition would be successful, experts said.

“In Canada, it is almost impossible not to be extradited, especially to our good friends the US,” said Robert Currie, professor of international criminal law at Dalhousie University in Halifax. He added that wealthy people, using all legal means, could prevent extradition for a few years.

In Canada, the bail system is largely based on community trust and connections and does not involve large cash deposits and commercial bail-borrowers as is the case in many US states.

Instead, in most cases, the defendant needs to find one or more “guarantees” – usually a family member or lifelong friend who pledges collateral, often in the form of property. More importantly, they also agree to supervise the accused, make sure the accused keeps bail set by the court, and notify the police of any violations.

In Mr. Nygard’s case, none of his 10 children, ex-girlfriends, or longtime businesspeople who helped set up his business appeared in court as a proposed surety. Instead there were two employees: one a former site manager with a criminal record of cocaine trafficking and a previous association with the Hells Angels motorcycle club, and the other a former director who still works for Mr Nygard overseeing the company’s bankruptcy proceedings.

Categories
Health

New Covid variants are going to ‘hit us fairly onerous,’ says Dr. Peter Hotez

Dr. Peter Hotez, co-director of the Center for Vaccine Development at Texas Children’s Hospital, says the US is “facing a tough journey” as new variants of Covid spread across the country.

“Because they are more transmissible, it means more Americans will be infected. Although the number of new cases has decreased slightly … the expectation now is that it will rise again because of these new variants.” “Hotez said in an interview on Thursday evening of” The News with Shepard Smith. “” More people will become infected, overwhelm hospital systems again, and possibly the death rate will rise, both from a combination of more new cases in general and one. ” slightly higher mortality rate, solely due to the variant by the type of variant. “

Health officials in South Carolina have confirmed two cases of the dangerous, highly communicable South African tribe of Covid. Officials said the cases appear unrelated and unrelated to a recent trip. Dr. Zeke Emanuel, a member of President Joe Biden’s Covid Advisory Board, said that is why the South African exposure is so worrying.

“This is worrying because these two people have no evidence of travel, and it means that the South African variant, which is more worrying than even the British variant, is about and in the community,” said Emanuel.

Hotez told host Shep Smith that the new strains were even more problematic because “we weren’t looking”.

“We’ve done so poorly on genome sequencing that we’re picking up these British, South African, and Brazilian variants. So we know they’re in South Carolina, but they could be elsewhere,” said the dean of the National School of Tropical Medicine on Baylor College of Medicine.

The Centers for Disease Control and Prevention warned that the British variant, also known as B117, could dominate the US by spring. Hotez said the key to protecting the population is to vaccinate people faster.

“The bottom line is that we need to find a way to vaccinate the American people faster than current projections,” Hotez said. “First, to reduce hospital stays and deaths, but also to stay one step ahead of these variants. If we can vaccinate three-quarters of the American population, we could potentially interrupt transmission and prevent some of these new variants from becoming dominant.”

Categories
Health

Peter Thiel-backed psychedelics start-up ATAI targets schizophrenia

LONDON – ATAI Life Science, a Peter Thiel-backed start-up, has acquired a majority stake in Recognify, a company that develops drugs to treat schizophrenia.

ATAI is headquartered in Berlin and aims to manufacture psychedelics that can be used to treat mental disorders. Recognify, meanwhile, is specifically aiming to create a drug that can be used to treat the cognitive impairment associated with schizophrenia, or CIAS.

The latter company was co-founded by the German-American biochemist Thomas Sudhof, who received a Nobel Prize in Physiology or Medicine in 2013.

The terms of the deal were not disclosed, but ATAI said it was in the “tens of millions”.

ATAI, calling itself a drug development platform, was formed to acquire, incubate, and develop psychedelics and other drugs that can be used to treat depression, anxiety, addiction, and other mental illnesses. In return for a controlling stake in the drugs they develop, ATAI helps scientists raise money, work with regulators, and conduct clinical trials.

Treatment of schizophrenia

Recognify’s lead drug, RL-007, has been tested in nine clinical studies on 508 people, including rats, according to ATAI. Clinical trial results were not published.

Srinivas Rao, co-founder and chief scientist of ATAI, told CNBC through Zoom that Recognify has developed a “very interesting” compound that has been shown to have benefits.

“Things like verbal memory and things like that were actually greatly enhanced with this connection,” said Rao. “And that’s something that is deficient in patients with schizophrenia. So that’s really the requirement here. We want to extend the results that exist now to the schizophrenic population.”

Schizophrenia affects around 20 million people, according to the World Health Organization, which results in people hearing voices and seeing things that are not real through hallucinations, and can also cause disorganized and confused thinking.

IPO plans

The news of the Recognify deal comes after ATAI raised $ 125 million from investors like Thiel in November, ahead of a listing this year. The total investment in the company is now over $ 210 million.

“The great virtue of ATAI is taking mental illness as seriously as we should have,” said Thiel, co-founder of Palantir and PayPal, in a statement shared with CNBC at the time. “The company’s most valuable asset is its urgency.”

The two-year company, which has offices in Berlin, New York and San Diego, currently works with around 10 drug development companies.

According to an industry source who wanted to remain anonymous due to the nature of the discussions, there are plans to launch ATAI with a value between $ 1 billion and $ 2 billion in the next few months.